Introduction
Equine influenza (EI) is a highly contagious viral disease that typically manifests in fully susceptible animals with clinical signs of a frequent, dry, harsh, hacking cough, a serous and subsequently mucopurulent nasal discharge and fever. EI remains a significant disease across most of the globe, primarily due to its ability to cause extensive disruption to equestrian breeding, training and competition schedules. As a result of this economically important threat, vaccination against EI has become widespread and mandatory in many equestrian disciplines.
Virology
EI is caused by an orthomyxovirus of the genus influenza A, which is divided into serological subtypes based on the haemagglutinin (HA) and neuraminidase (NA) surface glycoproteins. All currently circulating EI viruses belong to the H3N8 subtype and can be traced back phylogenetically to 1963 when first isolated from racehorses in Miami, USA. EI viruses, like other influenza viruses, undergo antigenic drift due to the gradual accumulation of mutations in the genes encoding HA and NA. These mutations eventually lead to significant antigenic changes in the virus that can lead to breakdown of immunity. The global distribution of EI viruses is continually monitored by a small network of OIE (World Organisation for Animal Health) reference laboratories, which characterise EI viruses that are submitted to them.
Phylogenetic analysis of HA sequences show that between 1963 and the mid-1980s H3N8 EI viruses evolved as a single lineage before diverging into two distinct lineages, based on their geographic distribution; so-called American-lineage and European-lineage viruses. Americanlineage viruses subsequently spread to Europe and the number of outbreaks caused by European-lineage viruses gradually diminished, such that they may now have become extinct. Three sub-lineages of the American-lineage emerged, of which the Florida sublineage became predominant. The Florida sub-lineage has itself subsequently diverged into two antigenically distinct clades, known as Florida clade 1 (FC1) and Florida clade 2 (FC2).
Surveillance to inform vaccine strain selection
Antigenic drift and genetic evolution of EI viruses are monitored regularly by a panel of EI experts (Expert Surveillance Panel or ESP), which includes representatives from OIE reference laboratories. Data from outbreaks of EI, particularly in vaccinated horses, and the antigenic and genetic characteristics of EI viruses are reviewed annually. Recommendations are then made on the need to update vaccines and these are published in the OIE Bulletin (http://www.oie.int/publications-and-documentation/bulletins-online/). Since 2010, the ESP has recommended that vaccines for the international market should contain representative H3N8 EI viruses from both FC1 and FC2, with no requirement stipulated any longer for European lineage H3N8 or H7N7 EI viruses. This recommendation is based on the evident continued co-circulation of these two clades internationally and the continuing antigenic evolution of their constituent viruses. The timely updating of influenza vaccines with relevant viruses is essential to minimise the threat of EI to equine populations worldwide. As of April 2017 among four brands of EI vaccine used in the UK, only one product contained representatives of both FC1 and FC2 strains (Proteq Flu; Merial), one other contained an FC1 strain but not a FC2 strain (Equilis Prequenza; MSD) and the other two products contained neither FC1 nor FC2 strains (Duvaxyn IE; formerly Elanco and Equip F; Zoetis).
The latest global surveillance data on EI viruses show that FC1 viruses continue to predominate on the American continent (North and South) but were also responsible for large outbreaks of disease in South Africa, Japan and Australia, between 2003 and 2007. Similarly, FC2 viruses continue to predominate in Europe but have also caused large outbreaks in India, Mongolia and China. FC1 viruses have spread to Europe (e.g. they were identified in the UK in 2007 and again in 2009) but have so far not predominated over FC2 viruses.
UK surveillance activity
In the UK the Animal Health Trust (AHT) runs a long-standing EI surveillance scheme that is intended to monitor genetic and antigenic changes in EI viruses circulating in the UK. The scheme is generously supported by the Horserace Betting Levy Board and provides free advice and free diagnostic testing for EI to UK veterinary practices that register with the scheme. When outbreaks of EI are detected in the UK the AHT are involved in their investigation and control and information is evaluated to try and establish if there has been failure of vaccination and if so what factors have contributed to this. There has, however, been no major outbreak of EI involving vaccinated horses since spring 2003, when many vaccinated racehorses in Newmarket became infected. Data from the scheme and allied investigations and research contributes to the annual ESP review of EI global activity.
Recent UK situation
Since March 2014 the AHT has confirmed 61 outbreaks of EI in the UK with annual totals of 31 outbreaks diagnosed in 2014, 22 outbreaks in 2015 but only seven outbreaks confirmed throughout 2016 (Table 1 ) and in 2017 only one serological diagnosis has been made up to the end of the first quarter. 
